StockData

MacroGenics vs Xencor

MGNX and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MGNX and XNCR compare

Xencor is the larger company, worth 20 times as much as MacroGenics ($2.6B against $131M).

MacroGenics grew revenue faster over the last twelve months (11.7% versus −28.6% for Xencor).

MacroGenics keeps more of each dollar of sales as profit, with a net margin of −8.7% compared with −156% at Xencor.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMGNXXNCR
Size and price
Market cap$131M$2.6B
Share price$2.05$34.50
Change, 1 year36.7%131%
Change, 5 years−89.1%−2.7%
Beta (5Y)0.53−0.05
Employees293260
StockData Score
Total score55
Valuation score00
Growth score11
Performance score3 (better)1
Health score13 (better)
Dividend score00
Valuation
P/S0.8× (better)24.4×
P/B3.0× (better)5.1×
FCF yield−50.2%−8.1% (better)
Fair value–$11.73
Margin of safety–−194%
Growth
Revenue growth (TTM)11.7% (better)−28.6%
Revenue growth, 5Y average7.3% (better)0.47%
Profitability
Operating margin−24.3% (better)−206%
Net margin−8.7% (better)−156%
FCF margin−39.1% (better)−198%
Return on equity−32.6%−29.1% (better)
Return on invested capital–−26.6%
Financial health
Debt / equity–0.21
Interest coverage−2.4× (better)−8.0×
Current ratio2.966.39 (better)
Altman Z-score−4.025.01 (better)
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions76.4%113%
Held by insiders6.2%1.6%
Insider net buying, 12 months−$129K (better)−$7.5M
Short interest, % of float8.3%17.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.